Compound-testing in a murine model for COVID-19 show that the prophylactic or therapeutic application of Apilimod and other PIKfyve inhibitors, the former being considered for human Phase II trials, worsens disease outcome with higher lung viral load and mortality.
- James Logue
- Arup R. Chakraborty
- Matthew B. Frieman